Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 22.05 USD -1.43% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Nurix Therapeutics Inc?
Write Note

Nurix Therapeutics Inc
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nurix Therapeutics Inc
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Nurix Therapeutics Inc
NASDAQ:NRIX
PP&E Gross
$48m
CAGR 3-Years
93%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
PP&E Gross
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nurix Therapeutics Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 242 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. The company leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.

NRIX Intrinsic Value
10.54 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Nurix Therapeutics Inc's PP&E Gross?
PP&E Gross
48m USD

Based on the financial report for Nov 30, 2023, Nurix Therapeutics Inc's PP&E Gross amounts to 48m USD.

What is Nurix Therapeutics Inc's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
61%

Over the last year, the PP&E Gross growth was 63%. The average annual PP&E Gross growth rates for Nurix Therapeutics Inc have been 93% over the past three years , 61% over the past five years .

Back to Top